Chongqing Lummy Pharmaceutical Co., Ltd. (SHE:300006)
China · Delayed Price · Currency is CNY 4.870
+0.140 (2.96%)
Jul 31, 2026, 3:04 PM CST
SHE:300006 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 759.5 | 775.69 | 795.6 | 895.59 | 884.59 | 1,225 |
Revenue Growth | -6.57% | -2.50% | -11.16% | 1.24% | -27.80% | -22.63% |
Gross Profit Gross Profit Growth | 407.87 | 420.37 | 499.06 | 612.44 | 645.93 | 844.3 |
Operating Income Operating Income Growth | -73.99 | -77.75 | -74.79 | -56.71 | -105.89 | -133.43 |
Net Income Net Income Growth | -135.94 | -134.71 | -87.8 | -8.93 | -68.71 | -100.53 |
Earnings Per Share EPS Growth | -0.13 | -0.13 | -0.08 | -0.01 | -0.07 | -0.10 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Pharmaceutical Manufacturing Pharmaceutical Manufacturing Growth | 590.72 | 668.99 | 739.21 | 753.6 | 1,051 |
Pharmaceutical Distribution Pharmaceutical Distribution Growth | 152.16 | 103.92 | 119.58 | 93 | 134.7 |
Service income Service income Growth | 19.08 | 9.63 | 15.46 | 18.86 | 24.72 |
Unallocated Other Operating Income Unallocated Other Operating Income Growth | 13.73 | 13.06 | 21.34 | 19.13 | 14.61 |
Total Total Growth | 775.69 | 795.6 | 895.59 | 884.59 | 1,225 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 919.68 | 926.06 | 1,072 | 836.44 | 846.29 | 559.43 |
Total Debt Total Debt Growth | 396.48 | 373.48 | 494.59 | 270.79 | 365.27 | 219.32 |
Net Cash (Debt) Net Cash Growth | 523.2 | 552.58 | 577.51 | 565.65 | 481.02 | 340.11 |
Net Cash Growth | 5.07% | -4.32% | 2.10% | 17.59% | 41.43% | - |
Net Cash Per Share Net Cash Per Share Growth | 0.50 | 0.52 | 0.55 | 0.54 | 0.46 | 0.34 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 34.79 | 26.04 | 185.03 | 81.53 | 57.13 | 108.28 |
Capital Expenditures CapEx Growth | -37.1 | -41.75 | -78.62 | -59.32 | -68.18 | -38.66 |
Free Cash Flow Free Cash Flow Growth | -2.31 | -15.71 | 106.41 | 22.21 | -11.05 | 69.63 |
Free Cash Flow Growth | - | - | 379.04% | - | - | -61.32% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Gross Margin | 53.70% | 54.19% | 62.73% | 68.38% | 73.02% | 68.91% |
Operating Margin | -9.74% | -10.02% | -9.40% | -6.33% | -11.97% | -10.89% |
Pretax Margin | -19.58% | -18.93% | -9.49% | 0.40% | -8.51% | -8.65% |
Profit Margin | -17.90% | -17.37% | -11.04% | -1.00% | -7.77% | -8.21% |
FCF Margin | -0.30% | -2.02% | 13.37% | 2.48% | -1.25% | 5.68% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Forward PE | - | 139.34 | 139.34 | 139.34 | 139.34 | 139.34 |
P/FCF Ratio | - | - | 36.32 | 176.84 | - | 103.43 |
PS Ratio | 6.77 | 7.00 | 4.86 | 4.39 | 4.55 | 5.88 |